SPRY
Ars Pharmaceuticals
$5.06
−$0.17 (−3.25%)Sep 10, 2026
Key metrics
The numbers that frame SPRY today
- Market cap
- $503.20M
- P/E (TTM)
- -2.3
- EV / FCF
- -3.4
- Gross margin
- 71.4%
- EV / Sales
- 5.7
- ROIC
- -54.5%
- Div yield
- 0%
- Debt / equity
- 13.7
- 52wk Low
- $4.91
- 52wk High
- $13.15
Growth
Revenue and earnings trend for SPRY
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about SPRY
Is Ars Pharmaceuticals a good buy?
No. Ars Pharmaceuticals has weak quality and poor momentum. Both signals point to a weaker setup. Growth looks poor. That could put pressure on the long-term business case. We think Ars Pharmaceuticals is selling at a very high price.
What is the market capitalization of SPRY?
Ars Pharmaceuticals's market capitalization is $503.20M.
What is the P/E ratio for SPRY stock?
Ars Pharmaceuticals's current P/E ratio is -2.3.
What is the 52-week high for SPRY stock?
The 52-week high for Ars Pharmaceuticals is $13.15. The current close of $5.06 is 61.5% below that high.
What is the 52-week low for SPRY stock?
The 52-week low for Ars Pharmaceuticals is $4.91. The current close of $5.06 is 3.1% above that low.
Does SPRY stock pay dividends?
Ars Pharmaceuticals does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for SPRY?
Ars Pharmaceuticals's Debt / Equity ratio is 13.72.